PathShodh Healthcare sees its Lab-on-Palm ‘anuPath’ to transform testing of vital parameters

Nandita Vijay, BengaluruWednesday, July 4, 2018, 08:00 Hrs  [IST]

PathShodh Healthcare, a medical device research and development company incubated at the Indian Institute of Science (IISc) in Bengaluru is confident that its Lab-on-Palm ‘anuPath’ is set to revolutionise diagnostic testing of vital parameters for diabetes, kidney failure, anaemia and malnutrition.

The product is waiting for clearance from the Drugs Controller General of India (DCGI) for its first product Lab-on-Palm known as anuPath which is a multi analyte device. Simultaneously the company is also trying for CE certification from Europe.

anuPath is a single hand held device designed to measure eight different vital parameters for diabetes, kidney failure, anaemia and malnutrition. The technology has been developed at Centre for Nano Science and Engineering (CeNSE), IISc. Eight international patents in Japan, USA, UK, China and India are filed.

“This is a one-of-a kind of product not only in India but globally too. With the new medical device regulations 2018 for IVD, we are in the process of getting the clearance from the DCGI”, Dr. Vinay Kumar, co-founder and CEO, PathShodh Healthcare told Pharmabiz.

The device has completed clinical validation on over 25,000 clinical samples at NABL accredited pathology labs and hospitals. The company is also a finalist for the Design: Impact Awards by Titan in collaboration with Tata Trusts. It has published the clinical data in peer reviewed international journals.

“Our objective is to develop the novel technologies for health gadgets for public health problems and chronic diseases. anuPath is for clinicians and health workers. The other products in pipeline are the devices for individual use or for home diagnostics use,” he added.

Dr. Kumar completed his Ph.D. at the IISc and the device was developed along with Prof. Navakanta Bhat, chairperson, Centre for Nano Science and Engineering. Now PathShodh Healthcare, incubated in 2015, will take this technology for mass population benefits. Currently a team of 15 personnel work in different domains of biochemistry/chemistry, hardware, software, manufacturing and marketing.

There are two parts of the product: an electronic meter and diagnostic test strips. We have developed a manufacturing facility for diagnostic test strips in Bengaluru. We are working towards the scaling up our capacities to serve a large population. The product is in the market now and some trusts and foundations including Tata Trusts are using the same for the mass screening across different states, said Dr. Kumar.

In India, the scene is positive for lifesciences start-ups. There is a need to solve the healthcare problems. This country is a big market for novel technologies that are accurate, cost-effective and easily available. If the technology is tried and tested, then private equity and venture capital players are receptive to funding. But for products in proof of concept stage do not appeal to PEs and VCs. The challenge is that India needs a conducive manufacturing environment. The reality is raw materials required to manufacture are imported and for start-ups it increases the cost of final product, he noted.